#### Available online on <u>www.ijpcr.com</u>

International Journal of Pharmaceutical and Clinical Research 2023; 15(5); 1197-1202

**Original Research Article** 

# A Longitudinal Study on Lymphedema in Patients Undergoing Axillary Dissection for Carcinoma Breast

Najeeb P.M.<sup>1</sup>, S. Sreekumar<sup>2</sup>

<sup>1</sup>Junior Resident, Department of General Surgery, Government Medical College Thrissur, Thrissur, Kerala, India.

<sup>2</sup>Professor and HOD, Department of General Surgery, Government Medical College Kannur, Kannur, Kerala, India

Received: 25-03-2023 / Revised: 25-04-2023 / Accepted: 15-05-2023 Corresponding author: Dr. S. Sreekumar Conflict of interest: Nil

#### Abstract

**Background:** This study was conducted to evaluate the occurrence of lymphedema in patients undergoing axillary dissection and/or irradiation for breast cancer and also to determine the risk factors associated with the occurrence of lymphedema in these patients.

**Methods:** This was a hospital-based prospective study conducted among 198 patients who presented with carcinoma breast to the Department of General Surgery, Government, Medical College, Thrissur over a period of one year after obtaining clearance from the institutional ethics committee and written informed consent from the study participants.

**Results:** Out of 198 patients with a mean age of 53.8 years, a modified radical mastectomy was performed in 193 patients (97.5%), and 5 patients underwent breast conservation surgery (2.5%). 65.2% patients were diagnosed with stage II disease. 18.2 % of participants had post-operative wound infection or seroma. Of the 198 participants, 18 (9.1%) had >/= 10 lymph nodes that tested positive for malignant cells on HPE. The incidence of lymphedema was 8.1 %.

**Conclusion:** Approximately 8% of breast cancer patients in our study developed clinically significant lymphedema. Non-dominant side malignancy, advanced stage of disease, post-operative wound infection, seroma, large nodal burden and systemic therapy are significant risk factors for lymphedema development. Irradiation had no significant effect on the development of lymphedema.

Keywords: Carcinoma Breast, Lymphedema (LE)

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

## Introduction

Breast cancer is by far the most commonly diagnosed cancer in women worldwide, accounting for 21% of all cancers diagnosed in women. [1] In India, breast cancer incidence is on the rise and has now become the most common cancer among women, having overtaken cervix in all the cancer registries, rural or urban. [2] Quality of life and long-term effects of treatment have become increasingly important for breast cancer patients due to improved survival outcomes. [3,4,5]

A potential side effect of breast cancer surgery is lymphedema (LE), a chronic condition characterized by swelling of the arm, hand, breast, or trunk, which may develop from the accumulation of lymphatic fluid in the interstitial tissues. Lymphedema is known to have detrimental effects on quality of life due to changes in body image, alterations in arm function, and increased complications such as infection and cellulitis. [6,7,8,9] Upper extremity LE is one of the most common complications after breast cancer surgery with a reported incidence of 6% to 30%. [10]

Lymphedema may present with different signs and symptoms including a feeling of heaviness or tightness in the limb, pain or discomfort, restricted range of motion, and swelling in a part or entire limb. With the early identification and management of lymphedema, we can help patients to maintain their quality of life by minimizing cosmetic, functional, psycho emotional, and potentially life-threatening complications. Risk factors for lymphedema development that are described in the literature include age, presence of co-morbid conditions, wound infection, obesity, stage of disease, axillary dissection, radiation and systemic therapy. [11,12,13] Univariate analysis of risk factors in the current study showed a correlation between increased lymphedema rates and advanced stage of disease, presence of co-morbid conditions, body surface area > 1.5 m and postoperative anthracycline-based chemotherapy locoregional and radiotherapy. However, only axillary irradiation and presence of co-morbid conditions have emerged as significant risk factors for lymphedema development in multivariate analysis. The aim of this study is to assess the risk of upper limb lymphedema in patients who underwent axillary dissection and to clarify the clinical, oncologic and therapeutic factors that could possibly influence this morbidity.

## **Aims and Objectives**

➤ To find out the occurrence of lymphedema in patients undergoing

axillary dissection and/or irradiation for breast cancer.

To determine the risk factors associated with the occurrence of lymphedema in these patients.

# Materials & methods

This was a hospital-based prospective study conducted among 198 patients who presented with carcinoma breast to the Department of General Surgery, Government, Medical College, Thrissur, over a period of one year after obtaining clearance from the institutional ethics committee and written informed consent from the study participants.

# **Inclusion Criteria**

Patients above 18 years of age who are diagnosed with carcinoma breast and underwent axillary dissection during the study period.

## **Exclusion** Criteria

i) Not willing to participate,

ii) Presented with lymphedema itself (without neoadjuvant therapy)

# Sample Size

Using formula  $n = 4 pq/d^2$  for 5% level of significance where P is prevalence of lymphedema,

q= 100-p and d =20% of p

We have  $P = 33.5\%^{[14]}$ 

Using above formula, sample size  $(n) = 4X33.5X66.5/(6.7)^2$ 

Which is = 198.50

Therefore, my sample size = 198.

198 patients who underwent axillary dissection for carcinoma breast were studied.

## **Study Procedure**

Every patient (satisfying the inclusion & exclusion criteria) who gets admitted to General Surgery Department, Government Medical College, Thrissur, with carcinoma breast, (from one year following ethical clearance) were included in the study. Informed consent was obtained from all subjects. Data was collected from the patient according to the proforma. Patients were taken for surgery (modified radical mastectomy/ breast conservation surgery) after clearing the pre anesthetic checkups. The patient's bilateral upper limb sizes were measured prior to the procedure. Specimen was sent for HPE and later followed up. Upper limb sizes and adjuvant therapy data were later collected at 6 months and 1 year following surgery either through digital platform or in person.

## **Statistical Methods**

Collected data coded, entered into excel sheet, analysed using SPSS software and

expressed as percentages, means and deviation. standard The continuous variables like age, lymph nodes positive were summarised as mean and standard median deviation and and IOR. Categorical variables like age, BMI category, diabetes mellitus, and other clinical features, and types of treatment were summarised as frequency and proportions.

Association of development of lymphedema with continuous variables were analysed using unpaired t-test and categorical variables using Chi-square test or Fisher's exact test depending on distribution.

Results

able 1: Association between Side of Disease and Incidence of	Lym	nphedema	(N = 198)
--	-----	----------	-----------

Feature		No. of	No	Lymphoedema	<b>P-</b>	
		Patients	Lymphoedema	Present n = 16 (n,	Value	
			n = 182 (n, %)	%)		
Side of	Left	92	80, 87.0	12, 13.0	0.02*	
Disease	Right	106	102, 96.2	4, 3.8		
Dominant	Left	4	4, 100.0	0, 0	$1.0^{*}$	
Hand	Right	194	178, 91.8	16, 8.1		
* - Fisher's exact p-value						

Incidence of lymphedema was higher among those who had disease on the left side (p-value 02). In this study, the majority were right handed persons. Patients who were right-handed with carcinoma on left side had more incidence of lymphedema, which suggests that active movements of the limb play a significant role in reduction of post-operative lymphoedema.

Table 2: Association between Stage of Disease and Incidence of Lymphedema (N = 198)

Feature		No. of Patients	No Lymphedema n = 182 (n, %)	Lymphedema Present n = 16 (n, %)	P- Value
Stage of	Ι	36	36, 100.0	0, 0	$0.002^{*}$
disease	II	129	121, 93.8	8, 6.2	
	III	31	23, 74.2	8, 25.8	
	IV	2	2, 100	0, 0	
* - Fisher's exact p-value					

Majority of patients belonged to stage II & III of disease.

Incidence of lymphedema was higher among those who had the disease diagnosed at stage III followed by stage II.

Lymphedema (N = 198)						
Feature		No. of	No	Lymphedema	Р-	
		Patients	Lymphedema	Present n = 16	Value	
			n = 182 (n, %)	(n, %)		
Post-op Surgical Site	Yes	36	26, 72.2	10, 27.8	<.001#	
Infection/ Seroma	No	162	156, 96.3	6, 3.7		
# - Chi Square P-Value						

 Table 3: Association between Post-Op Surgical Site Infection and Incidence of Lymphedema (N = 198)

Incidence of lymphedema was higher among those who had post-op surgical site infection/seroma (p-value <.001).

# Table 4: Association between Number of Lymph Nodes and Incidence of Lymphedema (N = 198)

Feature		No. of Patients	No Lymphedema n = 182 (n, %)	Lymphedema Present n = 16 (n, %)	P- Value
No. of Lymph Nodes	< 10	180	175, 97.2	5, 2.8	<.001*
	>= 10	18	7, 38.9	11,61.1	-
* - Fisher's exact p-value					

Incidence of lymphedema was higher among those who had more than 10 positive lymph nodes (p-value <.001).

# Table 5: Association between Neoadjuvant Chemotherapy and Incidence of Lymphedema (N = 198)

Feature	No. of		No. of		No Lymphedema n	Lymphedema Present	<b>P-Value</b>
	Pati	ents	= 182 (n, %)	n = 16 (n, %)			
Neoadjuvant	Yes	36	29, 80.6	7, 19.4	0.006#		
Chemotherapy	No	162	153, 94.4	9, 5.6			
# - Chi Square P-Value							

Neoadjuvant chemotherapy was significantly associated with the development of lymphedema, with a higher incidence among those who received neoadjuvant chemotherapy (p-value = .006).

The mean age of participants was 53.8 years, which was not statistically significant.

179 participants had a BMI of 30 kg/m2, while the rest had a BMI greater than or equal to 30 kg/m2. BMI was not significantly associated with the incidence of lymphedema (p-value 0.19).

Modified Radical Mastectomy (MRM) was done in 193 patients, and 5 patients underwent Breast Conservation Surgery (BCS), which, when compared, came out to be not significant with incidence of lymphedema.

Radiotherapy (p value - 0.63) & hormonal therapy (p value - 0.73) were not statistically associated with the incidence of lymphedema.

## Discussion

The majority of breast cancer patients in developing nations, including India, continue to present with locally advanced stages that demand a thorough axillary dissection. Our study shows that nearly 65% of patients present with locally advanced disease.

Lymphedema following breast cancer treatment continues to be a significant long-term morbidity in the current era. Lymphedema is difficult to cure once it develops. Although there is no definite recognized or established strategy of preventing the onset of this dreaded consequence, prevention through proper surgical technique, arm care after surgery, exercises, and massage therapy may help reduce the incidence and/or severity. [14]

This study should help us generate some more information on the incidence of lymphedema in the patients operated here, so that we can base our future strategies for the management of lymphedema more effectively.

Thus, we at the "Department of Surgery, Government Medical College, Thrissur" have made a sincere attempt to find out the incidence of lymphedema in carcinoma breast following axillary dissection and the possible risk factors for the same. We have also compared our studies with other studies done previously. A brief outline of the studies compared is given below. In the present study, the overall incidence of lymphedema was 16 out of 198 patients (8.1%), which is comparable to some other studies. [9]

Participant's age, BMI (kg/m<sup>2</sup>), radiotherapy and hormonal therapy were not significantly associated with the incidence of lymphedema, whereas previous studies showed a positive association of lymphedema with age, BMI and radiotherapy. [11,12,13]

In our study, lymphedema was more common in patients who had carcinoma in their non-dominant hand, which indirectly implies that post-operative limb usage and arm exercises play a significant role in reducing the chances and severity of lymphedema. Similar inferences was earlier noted in Sandra C. Hayes et al. study. [7]

Axillary dissection in an advanced stage of the disease can predispose to the development of lymphedema as per our study. In this study, it showed a significant p value of 0.002. Similarly, Pramod R. Pillai et al. conducted a study in 2011 on "Incidence of Lymphedema in Indian Patients Undergoing Axillary Dissection for Breast Cancer" at Amrita Institute of Medical Sciences, Kochi and found a correlation between increased lymphedema rates and advanced stages of the disease. [15]

In the present study, postoperative wound infection and/or seroma formation increases the risk of lymphedema with a significant p value of <0.001. This is in accordance with the study results of Segerstorm K et al. [13]

In our study, 18 (9.1 %) out of the 198 participants had 10 or more lymph nodes that tested positive for malignant cells in histopathology. Of which 11 patients developed lymphedema among the total 16 cases of lymphedema. It implies pathological nodal status have a significant role in lymphedema formation. [15]

A study conducted by Sandra A. Norman et al. showed that ALND [HR, 2.61; 95% confidence interval (95% CI), 1.77-3.84] and chemotherapy, specifically multi agent therapies with anthracycline (HR, 1.46; 95% CI, 1.04-2.04), were the only treatments significantly associated with increased lymphedema risk in standard multivariable analyses.[16] In the present study, there was also a significant relationship between chemotherapy and neoadjuvant lymphedema especially (anthracycline chemotherapy based regimen) with a p-value of 0.006 (15 out of 16 cases of lymphedema patients had undergone neoadjuvant chemotherapy).

# Conclusion

Approximately 8% of breast cancer patients in our study developed clinically significant lymphedema.

Non-dominant side maligancy, advanced stage of disease, post-operative wound infection/ seroma, large nodal burden and systemic therapy were significant risk factors for lymphedema development as per our study. Prevention by means of diagnosis at an early stage of the disease, refined technique to minimize wound infection/seroma, post-operative arm care and exercises can reduce the development and severity of lymphedema.

# References

- Parkin DM. The global burden of cancer. Semin Cancer Biol. 1998; 8(4): 219-35.
- Development of cancer atlas of India-A project of National Cancer Registry Program (Indian Council of Medical Research). First All India Report. 2002; 1:11-8.
- 3. Khan F, Amatya B, Pallant JF, Rajapaksa I. Factors associated with long-term functional outcomes and psychological sequelae in women after breast cancer. Breast. 2012;21(3):314-20.
- Rief W, Bardwell WA, Dimsdale JE, Natarajan L, Flatt SW, Pierce JP. Long-term course of pain in breast cancer survivors: a 4-year longitudinal study. Breast Cancer Res Treat. 2011; 130(2):579-86.
- Ahmed RL, Prizment A, Lazovich D, Schmitz KH, Folsom AR. Lymphedema and quality of life in breast cancer survivors: the Iowa Women's Health Study. J Clin Oncol. 2008;26(35):5689-96.
- Sakorafas GH, Peros G, Cataliotti L, Vlastos G. Lymphedema following axillary lymph node dissection for breast cancer. Surg Oncol. 2006;15(3): 153-65.
- Hayes SC, Janda M, Cornish B, Battistutta D, Newman B. Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. J Clin Oncol. 2008;26(21):3536-42.
- 8. Jager G, Doller W, Roth R. Quality-oflife and body image impairments in patients with lymphedema. Lymphology. 2006;39(4):193-200.

- Miller CL, Specht MC, Skolny MN, Horick N, Jammallo LS, O'Toole J, et al. Risk of lymphedema after mastectomy: potential benefit of applying ACOSOG Z0011 protocol to mastectomy patients. Breast Cancer Res Treat. 2014; 144:71-7.
- 10. Clark B, Sitzia J, Harlow W. Incidence and risk of arm oedema following treatment for breast cancer: a threeyear follow-up study. QJM. 2005; 98(5): 343-8.
- Kissin MW, Querrei DR, Easton D, Westbury G. Risk of lymphedema following the treatment of breast cancer. Br J Surg. 1986;73(7):580-4.
- 12. Ryttov N, Holm NV, Quist N, Blichert-Toft M. Influence of adjuvant radiotherapy on the development of late arm lymphedema and impaired shoulder mobility after mastectomy for carcinoma of breast. Acta Oncol. 1988; 27(6):667-8.
- Segerstorm K, Bjerle P, Graffman S, Nystrom A. Factors that influence the incidence of brachial oedema after treatment of breast cancer. Scand J Plast Reconstr Surg Hand Surg. 1992; 26(2):223-37.
- 14. Deo SV, Ray S, Rath GK, Shukla NK, Kar M, Asthana S, Raina V (2004) Prevalence and risk factors for development of lymphedema following breast cancer treatment. Indian J Cancer. 2004; 41(1):8–12.
- 15. Pillai PR, Sharma S, Ahmed SZ, Vijaykumar DK. Study of incidence of lymphedema in Indian patients undergoing axillary dissection for breast cancer. Indian J Surg Oncol. 2010;1(3):263-9.
- 16. Norman SA, Localio AR, Kallan MJ, Weber AL, Torpey HAS, Potashnik SL, et al. Risk factors for lymphedema after breast cancer treatment. Cancer Epidemiol Biomarkers Prev. 2010;19 (11):2734-46.

17.